Sinovac Biotech Ltd. (NASDAQ:SVA) announces encouraging preliminary results from a China-based Phase 1/2 clinical trial evaluating CoronaVac, its COVID-19 vaccine candidate, in 743 healthy volunteers.
Data from the Phase 2 portion showed a neutralizing antibody seroconversion rate north of 90% on a 0,14-day schedule (two shots 14 days apart).
On the safety front, there have been no severe adverse events reported.
It plans to file a report on the results and a proposed Phase 3 protocol to China’s National Medical Products Administration in the “near future.”
It is collaborating with Sao Paulo-based Instituto Butantan on Phase 3 trials to be conducted in Brazil.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.